ClinicalTrials.Veeva

Menu

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (TRIlogy-7)

Janssen (J&J Innovative Medicine) logo

Janssen (J&J Innovative Medicine)

Status and phase

Enrolling
Phase 3

Conditions

Multiple Myeloma

Treatments

Drug: Daratumumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Ramantamig

Study type

Interventional

Funder types

Industry

Identifiers

NCT07665450
79635322MMY3004

Details and patient eligibility

About

The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells [WBCs] called plasma cells) for whom stem cell transplant is not planned as initial therapy.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria
  • Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT
  • Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2
  • Must sign an informed consent form (ICF)
  • Measurable disease at screening as assessed by central laboratory as defined in the protocol

Exclusion criteria

  • Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone
  • Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients
  • Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose of trial intervention or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial
  • Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM
  • Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

1,000 participants in 2 patient groups

Arm A: Ramantamig plus Daratumumab (Ramantamig-D)
Experimental group
Description:
Participants will receive ramantamig D subcutaneous injection.
Treatment:
Drug: Ramantamig
Drug: Daratumumab
Arm B: Investigator's Choice (DVRd or DRd)
Active Comparator group
Description:
Participants will receive either daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) or daratumumab, lenalidomide, dexamethasone (DRd) as per investigator's choice.
Treatment:
Drug: Dexamethasone
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab

Trial contacts and locations

103

Loading...

Central trial contact

Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems